Recent years have seen a dramatic transformation in medical care for patients with acute myeloid leukemia (AML). Regulatory approvals and ongoing research for many novel therapeutics—from antibodies, newer cytotoxics, and epigenetic agents to FLT3, IDH, and BCL-2 inhibitors—have allowed for improved therapies that truly match the wide diversity of AML populations. These advances have informed the development of modern management protocols for FLT3- or IDH-mutant AML, secondary AML, and older patients who are considered fit or unfit for intensive therapy.
This collection of PeerView activities offers a well-rounded overview of the recent science that continues to support the ongoing integration of newly approved and novel strategies into AML care, as well as approaches for managing the unique spectrum of treatment-related adverse events with such therapies.
This activity has been designed to meet the educational needs of hematologist-oncologists and other clinicians involved in the management of AML.
Harry P. Erba, MD, PhD
Duke University Medical Center
Durham, North Carolina
Learn from one of our clinical experts by requesting a live in-person meeting at your institution or a live virtual webinar! In the context of a small, interactive group discussion, an expert in the field will review new directions and treatment choices for a variety of AML populations, including older patients fit or unfit for intensive therapy and mutation-specific AML types.
Download and complete the Meeting Request Form (or complete our online form) to request a live in-person meeting or turn-key virtual meeting with our expert faculty.
By requesting a meeting, you are attesting that you have read the CME/MOC Information for this activity.
Harry P. Erba, MD, PhD
Harry P. Erba, MD, PhD, will be joined by Naval Daver, MD, Courtney D. DiNardo, MD, MSCE, and Gail Roboz, MD, as expert presenters for this educational activity.
Harry P. Erba, MD, PhD
Harry P. Erba, MD, PhD, Naval Daver, MD, Courtney D. DiNardo, MD, MSCE, and Gail J. Roboz, MD
This educational curriculum is supported through educational grants from Bristol Myers Squibb and Jazz Pharmaceuticals, Inc.
Your meeting request has been submitted.
We invite you to learn more about PeerView's Institute Meetings here.
